vedolizumab subcutaneous (CLS-001) / Comera Life Sci - LARVOL DELTA

Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights (GlobeNewswire) - "Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company. Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel disease (IBD)."

Licensing / partnership • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights (GlobeNewswire) - "...Comera is introducing its lead pipeline candidate CLS-001 as a subcutaneous (SQ) formulation of vedolizumab, a currently marketed product for the treatment of IBD including Crohn’s disease and ulcerative colitis. Comera believes that a SQ formulation of vedolizumab could have significant advantages for patients and the healthcare system, compared to the current intravenous (IV) formulation."

Clinical • Immunology • Inflammatory Bowel Disease